AU2001285325A1 - Use of threo-methylphenidate compounds to enhance memory - Google Patents

Use of threo-methylphenidate compounds to enhance memory

Info

Publication number
AU2001285325A1
AU2001285325A1 AU2001285325A AU8532501A AU2001285325A1 AU 2001285325 A1 AU2001285325 A1 AU 2001285325A1 AU 2001285325 A AU2001285325 A AU 2001285325A AU 8532501 A AU8532501 A AU 8532501A AU 2001285325 A1 AU2001285325 A1 AU 2001285325A1
Authority
AU
Australia
Prior art keywords
threo
enhance memory
methylphenidate compounds
methylphenidate
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001285325A
Inventor
Mel H. Epstein
Kjesten A. Wiig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sention Inc
Original Assignee
Sention Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sention Inc filed Critical Sention Inc
Publication of AU2001285325A1 publication Critical patent/AU2001285325A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
AU2001285325A 2000-08-28 2001-08-28 Use of threo-methylphenidate compounds to enhance memory Abandoned AU2001285325A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22847800P 2000-08-28 2000-08-28
US60/228,478 2000-08-28
US23597200P 2000-09-28 2000-09-28
US60/235,972 2000-09-28
PCT/US2001/026774 WO2002017919A2 (en) 2000-08-28 2001-08-28 Use of threo-methylphenidate compounds to enhance memory

Publications (1)

Publication Number Publication Date
AU2001285325A1 true AU2001285325A1 (en) 2002-03-13

Family

ID=26922402

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001285325A Abandoned AU2001285325A1 (en) 2000-08-28 2001-08-28 Use of threo-methylphenidate compounds to enhance memory

Country Status (6)

Country Link
US (1) US20020103162A1 (en)
EP (1) EP1315495A2 (en)
JP (1) JP2004507503A (en)
AU (1) AU2001285325A1 (en)
CA (1) CA2420569A1 (en)
WO (1) WO2002017919A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20020161002A1 (en) * 2001-01-02 2002-10-31 Mel Epstein Use of catecholamine reuptake inhibitors to enhance memory
AU2003272608A1 (en) * 2002-09-19 2004-04-08 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
ES2373042T3 (en) * 2003-10-08 2012-01-30 Mallinckrodt Llc SOLUTION OF METHYLPHENIDATE AND ASSOCIATED PRODUCTION AND ADMINISTRATION PROCEDURES.
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
US20060100243A1 (en) * 2004-10-22 2006-05-11 Mark Froimowitz Methylphenidate analogs and methods of use thereof
AU2005313887B2 (en) * 2004-12-09 2011-10-27 Celgene Corporation Treatment using D-threo methylphenidate
US20120301405A1 (en) * 2005-05-02 2012-11-29 Kulli John C Simple Mechanical Procedure and Product for Deterring Substance Abuse.
US20080292665A1 (en) * 2007-05-25 2008-11-27 Kulli John C Simple mechanical procedure and product for deterring substance abuse
PL2818184T3 (en) * 2007-11-16 2019-06-28 Aclaris Therapeutics, Inc. Compositions and methods for treating Purpura
MX362571B (en) * 2011-07-28 2019-01-25 Kempharm Inc Star Methylphenidate-prodrugs, processes of making and using the same.
WO2014144952A2 (en) 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
US10441573B2 (en) 2015-12-09 2019-10-15 Brandeis University DBH inhibitors for treating memory loss
WO2018107132A1 (en) 2016-12-11 2018-06-14 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
GB9711032D0 (en) * 1997-05-30 1997-07-23 Johnson Matthey Plc Compound as a stimulant for the central nervous system
DE19906975B4 (en) * 1999-02-19 2004-04-15 Lts Lohmann Therapie-Systeme Ag Pharmaceutical form for the treatment of Alzheimer's dementia
US6025502A (en) * 1999-03-19 2000-02-15 The Trustees Of The University Of Pennsylvania Enantopselective synthesis of methyl phenidate
ES2210025T3 (en) * 1999-12-17 2004-07-01 Celltech Pharma Europe Limited PHARMACEUTICAL AGENT FOR THE TREATMENT OF CONVULSIVE STATES.
US6221883B1 (en) * 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
DE60027282T2 (en) * 2000-06-17 2007-04-12 Pharmaquest Ltd., Hamilton Use of l-threo-methylphenidate for the manufacture of a medicament for the treatment of depression

Also Published As

Publication number Publication date
JP2004507503A (en) 2004-03-11
EP1315495A2 (en) 2003-06-04
US20020103162A1 (en) 2002-08-01
CA2420569A1 (en) 2002-03-07
WO2002017919A2 (en) 2002-03-07
WO2002017919A3 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
AU2001291859A1 (en) Use of copolycarbonates
GB0025782D0 (en) Use of inhibitors
AU2001285325A1 (en) Use of threo-methylphenidate compounds to enhance memory
AU2002359659A1 (en) Cross reference to related application
AU2002217071A1 (en) Novel use of polyhydroxy compounds
AU2001269685A1 (en) Crystallization of 4-diphosphocytidyl-2-c-methylerythritol synthesis
AU2001244108A1 (en) Formulations for states of dehydration
GB0023289D0 (en) Determination of displacement
AU2001241037A1 (en) Use of piperidine benzoderivatives as fungicides
GB0029468D0 (en) Use of disazo compounds
EP1215193A3 (en) Production of 2-hydrocarbyl-2-adamantyl acrylate compounds
AU2001286861A1 (en) Use of methylphenidate compounds to enhance memory
AU2001272490A1 (en) Use of galiella lactone
AU5497701A (en) Direct slave addressing to indirect slave addressing
AU2001290731A1 (en) Structural prediction of allosterism
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
HK1054306A1 (en) Application of cosmetics
HK1053059A1 (en) New use of imidazotriazinon derivatives
AU2001249683A1 (en) Synthesis of thiazolium compounds
GB0112654D0 (en) Byte-swapping for efficient use of memory
AU3734901A (en) Use of amidines
AU2001259381A1 (en) Synthesis of diphosphinoarenes
AU2002220913A1 (en) Improvements relating to thermometers
TW424905U (en) Improved structure of drum-beater